China Medicine Corp. (CHME)
OTHER OTC:CHME
US Market

China Medicine (CHME) Income Statement

0 Followers

China Medicine Income Statement

Last quarter (Q ), China Medicine's total revenue was $17.55M, a decrease of -8.38% from the same quarter last year. In Q, China Medicine's net income was $2.22M. See China Medicine’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 09Dec 08Dec 07Dec 06Dec 05
Total Revenue
$ 65.75M$ 64.75M$ 53.65M$ 42.11M$ 23.99M$ 14.93M
Cost of Revenue
$ 43.75M$ 45.77M$ 38.07M$ 29.71M$ 15.02M$ 8.66M
Gross Profit
$ 22.00M$ 18.98M$ 15.57M$ 12.40M$ 8.97M$ 6.27M
Operating Expense
$ 10.30M$ 6.72M$ 4.65M$ 3.98M$ 2.79M$ 32.50K
Operating Income
$ 11.71M$ 12.27M$ 10.93M$ 8.41M$ 6.18M$ -32.50K
Net Non Operating Interest Income Expense
------
Other Income Expense
$ -2.22M$ -7.31M$ 85.62K$ 15.42K$ -1.13M$ 410.90K
Pretax Income
$ 9.48M$ 4.95M$ 11.01M$ 8.43M$ 5.98M$ 5.69M
Tax Provision
$ 3.76M$ 3.55M$ 2.01M$ 1.65M$ 1.23M-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 6.03M$ 1.72M$ 9.13M$ 6.88M$ 4.79M$ -32.50K
Basic EPS
$ -0.06$ 0.11$ 0.60$ 0.56$ 0.65$ -0.03
Diluted EPS
$ -0.21$ 0.11$ 0.60$ 0.50$ 0.63$ -0.03
Basic Average Shares
$ 95.62M$ 15.27M$ 15.17M$ 12.35M$ 7.35M$ 1.02M
Diluted Average Shares
$ 114.21M$ 15.41M$ 15.31M$ 13.66M$ 7.65M$ 1.02M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 54.05M$ 52.48M$ 42.72M$ 33.69M$ 17.81M$ 32.50K
Net Income From Continuing And Discontinued Operation
$ 6.03M$ 1.72M$ 9.13M$ 6.88M$ 4.79M$ -32.50K
Normalized Income
$ 7.95M$ 7.20M$ 9.06M$ 6.86M$ 5.69M$ -32.50K
Interest Expense
------
EBIT
$ 11.71M$ 12.27M$ 10.93M$ 8.41M$ 6.18M$ -32.50K
EBITDA
$ 13.41M$ 13.28M$ 11.35M$ 9.20M$ 6.35M$ -32.50K
Currency in USD

China Medicine Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis